Fig. 1 · Structure

Documents & Downloads

LY341495

Cat. No. A11484 CAS 201943-63-7

mGluR-2 antagonist

LY 341495 has been shown to be a highly potent and selective group II metabotropic glutamate receptor (mGluR-2) antagonist with Ki / IC50 values are 2.3, 1.3, 173, 990, 6800, 8200 and 22000 nM for human mGluR-2, mGluR-3, mGluR-8 , mGluR-7a, mGluR-1a, mGluR-5a and mGluR-4a.

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Target & Activity

Target Activity Value
mGluR1a IC50 7.8 μM
mGluR2 IC50 21 nM
mGluR3 IC50 14 nM
mGluR4 IC50 22 μM
mGluR5a IC50 8.2 μM
mGluR7 IC50 990 nM
mGluR8 IC50 170 nM

7 targets · Scroll to view more

Cellular Effect

Cell Line Activity Value Description Reference
CHO IC50 0.2 μM Antagonistic activity against stimulation of GTP (gamma) 35 S binding by glutamate in membranes from CHO cells expressing human mGluR2 [PMID: 11720869]

LY341495 Research Summary

This section summarizes 4 in vivo studies of LY341495 from 3 published references. In vivo models include adult male Sprague–Dawley rats (Charles River); male APP/PS1 transgenic mice.

LY341495 In Vivo Studies

In stressed adult male Sprague–Dawley rats, LY341495 reversed decreased sucrose preference at 48 hrs compared with the Stress/Vehicle group, with the effect sustained for 10 days. In male APP/PS1 transgenic mice, daily intraperitoneal LY341495 treatment improved the NOR discrimination index significantly compared with vehicle and also significantly improved the NLR discrimination index. In male Sprague–Dawley rats, LY341495 perfusion into the MDTN did not affect local glutamate levels. [1,2,3]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Sucrose Preference Following Stress in Rats

Animal study · Adult male Sprague–Dawley rats (Charles River) [1]

Adult male Sprague–Dawley rats received a single intraperitoneal injection of LY341495 at 3 mg/kg after stress. Compared with the Stress/Vehicle group, treatment showed a nonsignificant trend toward reversal of decreased sucrose preference at 24 hrs and reversed the decrease at 48 hrs, with the effect sustained for 10 days.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
sucrose preferenceReported result LY341495 produced a trend toward a reversal of stress-induced decreased sucrose preference at 24 hrs post-LY341495 treatment (not significant). LY341495 reversed the stress-induced decrease in sucrose preference 48 hrs after a single treatment, indicating a rapid antidepressant effect. †P < 0.01 compared to Stress/Vehicle group. The antidepressant effect of a single injection of LY341495 was[1]

Conditions shared by the study groups

Route
intraperitoneal (i.p.) injection
Treatment course
After 28 days of stress; a single intraperitoneal (i.p.) injection; tested 24 hrs, 48 hrs, and 10 days after drug administration.
Vehicle
saline
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
LY341495 3 mg/kgStress/Vehicle groupLY341495 produced a trend toward a reversal of stress-induced decreased sucrose preference at 24 hrs post-LY341495 treatment (not significant). LY341495 reversed the stress-induced decrease in sucrose preference 48 hrs after a single treatment, indicating a rapid antidepressant effect. †P < 0.01 compared to Stress/Vehicle group. The antidepressant effect of a single injection of LY341495 was sustained for 10 days. ‡P < 0.001 compared to Stress/Vehicle group.[1]
LY341495 3 mg/kg
Model: Adult male Sprague–Dawley rats (Charles River)
Methods and source locations

Compound reported in the paper: LY341495

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Methods (S1, S4, S6, S7); Figure 1 legend (S10, S11); Figure 2 legend (S12)

sucrose preference: sucrose preference; comparator: Stress/Vehicle group — Figure 1 legend (S10, S11); Figure 2 legend (S12)

LY341495 3 mg/kg · Methods (S4, S6, S7); Figure 1 legend (S10, S11); Figure 2 legend (S12)

Novel Object Recognition Discrimination in Transgenic Mice

Animal study · Male APP/PS1 transgenic mice [2]

Male APP/PS1 transgenic mice received daily intraperitoneal injections of LY341495 at 1.0 mg/kg for 7 consecutive days. The NOR discrimination index improved significantly compared with the vehicle group.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Discrimination index for NORReported result Discrimination index for NOR, showing a significant improvement in APP/PS1 mice treated with LY341495 compared to the vehicle group (*p < 0.05).[2]

Conditions shared by the study groups

Route
intraperitoneal injections
Treatment course
daily intraperitoneal injections of either LY341495 or vehicle for 7 consecutive days
Vehicle
saline
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
LY341495 1.0 mg/kgAPP/PS1 + VehicleDiscrimination index for NOR, showing a significant improvement in APP/PS1 mice treated with LY341495 compared to the vehicle group (*p < 0.05).[2]
LY341495 1.0 mg/kg
Model: Male APP/PS1 transgenic mice
Methods and source locations

Compound reported in the paper: LY341495

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Materials and Methods > Animals (S1); Materials and Methods > Drug Administration (S5, S6); Materials and Methods > Behavioral Tests (S10); FIGURE 1 legend (S139)

Discrimination index for NOR: Discrimination index for NOR; comparator: APP/PS1 + Vehicle — FIGURE 1 legend (S139)

LY341495 1.0 mg/kg · Materials and Methods > Drug Administration (S5); Materials and Methods > Behavioral Tests (S10); FIGURE 1 legend (S139)

Basal Extracellular Glutamate Following MDTN Perfusion in Rats

Animal study · Male Sprague‐Dawley rats [3]

Male Sprague–Dawley rats received LY341495 at 1 μmol L−1 by perfusion into the MDTN. LY341495 perfusion did not affect glutamate levels in the MDTN.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
basal extracellular glutamate levelReported result Neither perfusions with MK801 (50 μmol L−1), CPG (1 μmol L−1), LY341495 (1 μmol L−1), CPPG (100 μmol L−1) nor MUS (1 μmol L−1) into the MDTN affected glutamate levels in the MDTN[3]

Conditions shared by the study groups

Route
into the MDTN
Vehicle
dimethyl sulfoxide
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
LY341495 1 μmol L−1levels of MK801 pre‐perfusion of controlNeither perfusions with MK801 (50 μmol L−1), CPG (1 μmol L−1), LY341495 (1 μmol L−1), CPPG (100 μmol L−1) nor MUS (1 μmol L−1) into the MDTN affected glutamate levels in the MDTN[3]
LY341495 1 μmol L−1
Model: Male Sprague‐Dawley rats
Reported limits: Not stated in the sentences used: schedule.
Methods and source locations

Compound reported in the paper: LY341495

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

MATERIALS AND METHODS > Chemical agents (S5, S6); MATERIALS AND METHODS > Preparation of the microdialysis system (S11); RESULTS > Roles of Sxc, II‐mGluR, III‐mGluR, and GABAA receptor in the MDTN on mPFC MK801‐induced glutamate rise and MDTN MK801‐induced GABA reduction (S81); Figure 3 legend (S111)

basal extracellular glutamate level: basal extracellular glutamate level; comparator: levels of MK801 pre‐perfusion of control — RESULTS > Roles of Sxc, II‐mGluR, III‐mGluR, and GABAA receptor in the MDTN on mPFC MK801‐induced glutamate rise and MDTN MK801‐induced GABA reduction (S81); Figure 3 legend (S111)

LY341495 1 μmol L−1 · RESULTS > Roles of Sxc, II‐mGluR, III‐mGluR, and GABAA receptor in the MDTN on mPFC MK801‐induced glutamate rise and MDTN MK801‐induced GABA reduction (S81)

Novel Location Recognition Discrimination in Transgenic Mice

Animal study · Male APP/PS1 transgenic mice [2]

Male APP/PS1 transgenic mice received daily intraperitoneal injections of LY341495 at 1.0 mg/kg for 7 consecutive days. The NLR discrimination index improved significantly following treatment.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Discrimination index for NLRReported result Discrimination index for NLR, showing a significant improvement in APP/PS1 mice treated with LY341495 (*p < 0.05).[2]

Conditions shared by the study groups

Route
intraperitoneal injections
Treatment course
daily intraperitoneal injections of either LY341495 or vehicle for 7 consecutive days
Vehicle
saline
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
LY341495 1.0 mg/kgAPP/PS1 + VehicleDiscrimination index for NLR, showing a significant improvement in APP/PS1 mice treated with LY341495 (*p < 0.05).[2]
LY341495 1.0 mg/kg
Model: Male APP/PS1 transgenic mice
Methods and source locations

Compound reported in the paper: LY341495

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Materials and Methods > Animals (S1, S3); Materials and Methods > Drug Administration (S5, S6); Materials and Methods > Behavioral Tests (S10); FIGURE 1 legend (S140)

Discrimination index for NLR: Discrimination index for NLR; comparator: APP/PS1 + Vehicle — FIGURE 1 legend (S140)

LY341495 1.0 mg/kg · Materials and Methods > Drug Administration (S5); Materials and Methods > Behavioral Tests (S10); FIGURE 1 legend (S140)

Specifications

Manufacturer Adooq Bioscience
Actions Antagonist
CAS Number 201943-63-7
Applications mGluR-2 antagonist
Formula C20H19NO5
Molecular Weight 353.37
SMILES
C1[C@@H]([C@H]1[C@@](CC2C3=CC=CC=C3OC4=CC=CC=C24)(C(=O)O)N)C(=O)O

Storage & Solubility

In Vitro Solubility

Reported Solubility

No reported solubility data are available for this product.

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

LY341495 Research References

  1. [1] Dwyer JM, Lepack AE, Duman RS. mGluR2/3 blockade produces rapid and long-lasting reversal of anhedonia caused by chronic stress exposure. J Mol Psychiatry (2013). PMID: 25408908 DOI: 10.1186/2049-9256-1-15 Source material
  2. [2] Chen CP, Zhang T, E ED, et al. Targeting mGluR2/3 Signaling With LY341495 Restores Dentate Gyrus Function and Cognitive Performance in a Male Mouse Model of Alzheimer's Disease. CNS Neurosci Ther (2026). PMID: 42138018 DOI: 10.1002/cns.70916 Source material
  3. [3] Okada M, Fukuyama K, Kawano Y, et al. Memantine protects thalamocortical hyper-glutamatergic transmission induced by NMDA receptor antagonism via activation of system xc<sup/>. Pharmacol Res Perspect (2019). PMID: 30784207 DOI: 10.1002/prp2.457 Source material

Added to your cart

View Cart Checkout
Loading...